江苏吴中：公司产品连芩珍珠滴丸由处方药转换为非处方药

Core Viewpoint - The National Medical Products Administration of China has announced the reclassification of Lianqin Pearl Drops from prescription to over-the-counter medication, which may enhance market accessibility and sales potential for Jiangsu Wuzhong Pharmaceutical Group [1] Company Summary - Jiangsu Wuzhong Pharmaceutical Group's product, Lianqin Pearl Drops, has been officially transitioned from a prescription drug to an over-the-counter drug as per the announcement made on November 8 [1] - This change is based on the evaluation and review conducted by the National Medical Products Administration, indicating a regulatory shift that could positively impact the company's product distribution and consumer reach [1]